Versameb AG. (12/18/18). "Press Release: Versameb Ltd Raises CHF 5.3 Million for the Development of mRNA Therapies in Regenerative Medicine". Basel.

	Organisation	Versameb AG
	Product	mRNA-based drug
	Product 2	venture capital
	Index term	Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m
	Person	Metzger, Friedrich (Versameb 201910 CEO)
	Person 2	Meier, Roger (Versameb 201812 Board Chairman)

Versameb Ltd, a Swiss biopharmaceutical company, announced today the successful closing of a Seed B financing round, bringing the total capital raised to date to CHF 5.3 millions. Versameb Ltd is developing a technology platform for transformative therapies, focusing on regenerative medicine through the local application of messenger ribonucleic acid (mRNA).

“We are very pleased and grateful that our company is enjoying strong support from Swiss and international private investors with both scientific and financial background” commented Prof. Dr. Friedrich Metzger, Versameb’s CEO. He added: “Thanks to our team, we were able to kick-start our operations rapidly and create substantial value in a short period of time. Our technology has the potential to address a broad variety of currently unmet medical needs. I look forward to an exciting discovery and development journey.”

The proceeds will fund the extension of the platform technology, starting of pre-IND activities with the lead program and preclinical activities for additional regenerative medicine indications, and will secure the company’s corporate needs for organizational growth.

About Versameb Ltd

Versameb Ltd. a preclinical-stage biopharmaceutical company located in Basel, Switzerland. It became operational at the beginning of 2018 and employs a team of experts in drug discovery, research and development and complemented by life sciences venture professionals. Versameb’s proprietary platform technology optimizes the use of functional mRNA for the local application in various disease contexts. The current focus is on regenerative medicine, but the approach offers a broad array for the development of potential therapeutic options.

Contact for Media Enquiries

Roger Meier, Chairman of the Board

Peter Merian-Strasse 45 | CH-4052 Basel
+41 61 378 87 03 | +41 79 434 52 40
roger.meier@versameb.com

Record changed: 2020-05-28